But the development of what technology is under the microscope? We already know that Heinrich has been employed in determining the application of Phylogica's intracellular trap technology for the discovery of novel antimicrobial peptides which would penetrate the outer membrane of multi-resistant gram negative bacteria. Refer back to the following statement in Hottod's post;
"One of the reasons for the emergence of antibiotic resistance is believed to be the poor permeability of bacterial cell envelope to antimicrobial agents."
A while back, I highlighted this dot point on page 4 of this old presentation below.
– University of Queensland (IMB) for rapid mapping of a synthetic intracellular interactome and macrocyclisation
Why am I referencing this? Integration of the three technologies into the one product? Certainly a possibility.
8 July 2015
“These peptides would have a variety of uses, for example, as the basis for new pharmaceuticals to treat unmet medical needs that involve novel antibiotics and anti-cancer drugs.”
Now have a read of this passage taken from the April 26, 2012 announcement - "Phylogica granted patent for Synthetic Phylomer Libraries" and take note of what I've highlighted in bold font.
There are numerous applications of the newly patented technology, including the rational design of Phylomer libraries in parallel formats on solid surfaces, such as peptide arrays or beads. Array formats enable tens of thousands of peptides to be screened against multiple targets on a single miniature ‘chip’, significantly reducing the time and cost of identifying relevant drug candidates. The technology is highly amenable to scaling using multiple chips to screen hundreds of thousands to millions of peptides at a time. The technology also enhances various value-added uses of the Company’s platform, including direct phenotypic screening of Phylomer libraries for the discovery of, for example, novel antivirals, antibiotics or anticancer agents. In addition, array formats facilitate the construction of a range of high-density Phylomer libraries, which can be used for new applications of the platform, such as the identification of disease biomarkers for the development of novel diagnostic products.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)